Chemistry: molecular biology and microbiology – Treatment of micro-organisms or enzymes with electrical or... – Modification of viruses
Patent
1997-08-25
1999-02-16
Guzo, David
Chemistry: molecular biology and microbiology
Treatment of micro-organisms or enzymes with electrical or...
Modification of viruses
4352351, 4353201, 435325, C12N 1510, C12N 701, C12N 510, C12N 1586
Patent
active
058719822
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to the field of vectors useful in somatic gene therapy and the production thereof.
BACKGROUND OF THE INVENTION
Recombinant adenoviruses are capable of providing extremely high levels of transgene delivery to virtually all cell types, regardless of the mitotic state. High titers (10.sup.13 plaque forming units/ml) of recombinant virus can be easily generated in 293 cells (the adenovirus equivalent to retrovirus packaging cell lines) and cryo-stored for extended periods without appreciable losses.
The primary limitation of this virus as a vector resides in the complexity of the adenovirus genome. A human adenovirus is comprised of a linear, approximately 36 kb double-stranded DNA genome, which is divided into 100 map units (m.u.), each of which is 360 bp in length. The DNA contains short inverted terminal repeats (ITR) at each end of the genome that are required for viral DNA replication. The gene products are organized into early (E1 through E4) and late (L1 through L5) regions, based on e.g., Horwitz, Virology, 2d edit., ed. B. N. Fields, Raven Press, Ltd. New York (1990)!.
A human adenovirus undergoes a highly regulated program during its normal (1994)!. Virions are internalized by receptor-mediated endocytosis and transported to the nucleus where the immediate early genes, E1a and E1b, are expressed. Because these early gene products regulate expression of a variety of host genes (which prime the cell for virus production) and are central to the cascade activation of early delayed genes (e.g. E2, E3, and E4) followed by late genes (e.g. L1-5), first generation recombinant adenoviruses for gene therapy focused on the removal of the E1 domain. This strategy was successful in rendering the vectors replication defective, however, in vivo studies revealed transgene expression was transient and invariably associated with the development of severe Invest., 93:1885-1893 (1994); J. M. Wilson et al, Proc. Natl. Acad. Sci. USA, 85:4421-4424 (1988); J. M. Wilson et al, Clin. Bio., 3:21-26 (1991); M. Grossman et al, Som. Cell. and Mol. Gen., 17:601-607 (1991)!.
Adeno-associated viruses (AAV) have also been employed as vectors. AAV is a small, single-stranded (ss) DNA virus with a simple genomic organization (4.7 kb) that makes it an ideal substrate for genetic engineering. Two open reading frames encode a series of rep and cap polypeptides. Rep polypeptides (rep78, rep68, rep62 and rep40) are involved in replication, rescue and integration of the AAV genome. The cap proteins (VP1, VP2 and VP3) form the virion capsid. Flanking the rep and cap open reading frames at the 5' and 3' ends are 145 bp inverted terminal repeats (ITRs), the first 125 bp of which are capable of forming Y- or T-shaped duplex structures. Of importance for the development of AAV vectors, the entire rep and cap domains can be excised and replaced with a therapeutic or Tijsser, CRC Press, pp.155-168 (1990)!. It has been shown that the ITRs represent the minimal sequence required for replication, rescue, packaging, and integration of the AAV genome.
The AAV life cycle is biphasic, composed of both latent and lytic episodes. During a latent infection, AAV virions enter a cell as an encapsidated ssDNA, and shortly thereafter are delivered to the nucleus where the AAV DNA stably integrates into a host chromosome without the apparent need for host cell division. In the absence of helper virus, the integrated ss DNA AAV genome remains latent but capable of being activated and rescued. The lytic phase of the life cycle begins when a cell harboring an AAV provirus is challenged with a secondary infection by a herpesvirus or adenovirus which encodes helper functions that are recruited by AAV to aid in its parental ssDNA is expanded to duplex replicating form (RF) DNAs in a rep dependent manner. The rescued AAV genomes are packaged into preformed protein capsids (icosahedral symmetry approximately 20 nm in diameter) and released as infectious virions that have packaged either + or - ss DNA genomes follo
REFERENCES:
patent: 4797368 (1989-01-01), Carter et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5354678 (1994-10-01), Lebkowski et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5478745 (1995-12-01), Samulski et al.
patent: 5622856 (1997-04-01), Natsoulis
patent: 5753500 (1998-05-01), Shenk et al.
Y. Watanabe, "Serial Inbreeding of Rabbits with Hereditary Hyperlipedemia (WHHL-Rabbit)", Atherosclerosis, 36:261-268 (Jan., 1980).
K. Tanzawa et al., "WHHL-Rabbit: A Low Density Lipoprotein Receptor-Deficient Animal Model for Familial Hypercholesterolemia", FEBS Letters, 118(1):81-84 (Aug., 1980).
J. Goldstein et al, "Defective Lipoprotein Receptors and Atherosclerosis--Lessons form an Animal Counterpart of Familial Hypercholesterolemia", New Eng. J. Med., 309(5):288-296 (Aug. 4, 1983).
S. Ishibashi et al, "Hypercholesterolemia in Low Density Lipoprotein Receptor Knockout Mice and its Reversal by Adenovirus--Mediated Gene
J. Wilson et al., "Research Article--Transplantation of Allogeneic Hepatocytes into LDL Receptor Deficient Rabbits Leads to Transient Improvement in Hypercholesterolemia", Clin. Bio., 321-26 (Feb. 28, 1991)
M. Grossman et al., "Towards Liver-Directed Gene Therapy: Retrovirus-Mediated Gene Transfer into Human Hepatocytes", Som. Cell. And Mol. Gen., 17(Nov., 1991).
M. Boshart et al., "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus", Cell, 41:521-530.
S. Ishibashi et al, "Massive Xathomatosis and Atherosclerosis in Cholesterol-fed Low Density Lipoprotein Receptor-negative Mice", J. Clin.
J. Wilson, "Cystic Fibrosis--Vehicles for Gene Therapy", Nature,
M. Horwitz, "Adenoviridae and Their Replication", Virology, 2d edition, ed. B. N. Fields, Raven Press, Ltd., New York, Chapter 60, pp. 1679-1721 (1990).
Y.Yang et al., "Cellular Immunity to Viral Antigens Limits E1-deleted Adenoviruses for Gene Therapy", Proc. Natl. Acad. Sci. USA, 91:4407-4411 (May, 1994).
J. Wilson et al., "Research Article--Transplantation of Allogeneic Hepatocytes into LDL Receptor Deficient Rabbits Leads to Transient Improvement in Hypercholesterolemia", Clin. Bio., 321-26 (Feb. 28, 1991)
M. Grossman et al., "Towards Liver-Directed Gene Therapy: Retrovirus-Mediated Gene Transfer into Human Hepatocytes", Som. Cell. And Mol. Gen., 17(6):601-607 (Nov., 1991).
M. Boshart et al., "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus", Cell, 41521-530 (Jun., 1985).
K. Kozarsky et al., "In Vivo Correction of Low Density Lipoprotein Receptor Deficiency in the Watanabe Heritage Hyperlipidemic Rabbit with Recombinant Adenoviruses", J. Biol. Chem., 269(18):13695-13702 (May 6, 1994).
C. Laughlin et al., "Cloning of Infectious Adeno-associated Virus Genomes in Bacterial Plasmids", Gene, 23:65-73 (Jul., 1983).
J. Price et al., "Lineage Analysis in the Vertebrate Nervous System by Retrovirus-mediated Gene Transfer", Proc. Natl. Acad. Sci. USA, 84:156-160 (Jan., 1987).
J. Wilson et al, "A Novel Mechanism for Achieving Transgene Persistence in Vivo after Somatic Gene Transfer into Hepatocytes", J. Biol. Chem.,
T. Kost et al, "The Nucleotide Sequence of the Chick Cytoplasmic .beta.-actin Gene", Nucl. Acids Res., 11(23):8287-8301 (Dec. 11, 1983).
J. Schreibner et al, "Recombinant Retroviruses Containing Novel Reporter Genes", BioTechniques, 14(5):818-823 (May, 1993).
J. Riordan et al, "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA", Science, 245:1006-1073 (Sep., 8, 1989).
M. Brown et al, "A Receptor-Mediated Pathway for Cholesterol Homeostasis", Science, 232:34-46 (Apr. 4, 1986).
T. Yamamoto et al, "The Human LDL Receptor: A Cysteine-Rich Protein with Multiple Alu Sequences in its mRNA", Cell, 39:27-38 (Nov., 1984).
R. Samu
Fisher Krishna J.
Kelley William M.
Wilson James M.
Guzo David
The Trustees of the University of Pennsylvania
LandOfFree
Hybrid adenovirus-AAV virus and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybrid adenovirus-AAV virus and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid adenovirus-AAV virus and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2061518